The oncofetal Thomsen-Friedenreich carbohydrate antigen in cancer progression

Glycoconjugate Journal

Volumn 24, Issue 8, 2007, Pages 411-420

  Yu, Lu Gang ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Adhesion; Cancer metastasis; Galectins; Glycosylation; TF antigen

Indexed keywords

CARBOHYDRATE ANTIGEN; CARBOHYDRATE BINDING PROTEIN; GALECTIN; GLYCOCONJUGATE; LECTIN; THOMSEN FRIEDENREICH CARBOHYDRATE ANTIGEN; UNCLASSIFIED DRUG;

ANGIOGENESIS; CANCER GROWTH; CELL ADHESION; CELL COMMUNICATION; CELL INTERACTION; CELL PROLIFERATION; GLYCOSYLATION; HUMAN; IMMUNOTHERAPY; METASTASIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVIEW;

ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CA-15-3 ANTIGEN; CELL ADHESION; CELL PROLIFERATION; DISEASE PROGRESSION; ENDOTHELIUM; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 34848915825     PISSN: 02820080     EISSN: 15734986     Source Type: Journal    
DOI: 10.1007/s10719-007-9034-3     Document Type: Review

References (118)

1. Kim, Y.S., Gum, J. Jr, Brockhausen, I.: Mucin glycoproteins in neoplasia. Glycoconj. J. 13, 693-707 (1996)
2. Kim, Y.J., Varki, A.: Perspectives on the significance of altered glycosylation of glycoproteins in cancer. Glycoconj. J 14, 569-576 (1997)
3. Ono, M., Hakomori, S.: Glycosylation defining cancer cell motility and invasiveness. Glycoconj. J. 20, 71-78 (2004)
4. Springer, G.F.: Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy. J. Mol. Med. 75, 594-602 (1997)
5. Campbell, B.J., Finnie, I.A., Hounsell, E.F., Rhodes, J.M.: Direct demonstration of increased expression of Thomsen-Friedenreich (TF) antigen in colonic adenocarcinoma and ulcerative colitis mucin and its concealment in normal mucin. J. Clin. Invest. 95, 571-576 (1995)
6. Springer, G.F.: T and Tn, general carcinoma autoantigens. Science 224, 1198-1206 (1984)
7. Hanisch, F.G., Baldus, S.E.: The Thomsen-Friedenreich (TF) antigen: a critical review on the structural, biosynthetic and histochemical aspects of a pancarcinoma-associated antigen. Histol. Histopathol. 12, 263-281 (1997)
8. Yuan, M., Itzkowitz, S.H., Boland, C.R., Kim, Y.D., Tomita, J.T., Palekar, A., Bennington, J.L., Trump, B.F., Kim, Y.S.: Comparison of T-antigen expression in normal, premalignant, and malignant human colonic tissue using lectin and antibody immunohistochemistry. Cancer Res. 46, 4841-4847 (1986)
9. Itzkowitz, S.H., Yuan, M., Montgomery, C.K., Kjeldsen, T., Takahashi, H.K., Bigbee, W.L., Kim, Y.S.: Expression of Tn, sialosyl-Tn, and T antigens in human colon cancer. Cancer Res 49, 197-204 (1989)
10. Baldus, S.E., Zirbes, T.K., Hanisch, F.G., Kunze, D., Shafizadeh, S.T., Nolden, S., Monig, S.P., Schneider, P.M., Karsten, U., Thiele, J., Holscher, A.H., Dienes H.P.: Thomsen-Friedenreich antigen presents as a prognostic factor in colorectal carcinoma: a clinicopathologic study of 264 patients. Cancer 88, 1536-1543 (2000)
11. Shamsuddin, A.M., Tyner, G.T., Yang, G.Y.: Common expression of the tumour marker D-Galactose-ß-[1-3]-N-Acetyl-D-Galactosamine by different adenocarcinomas: evidence of field effect phenomenon. Cancer Res. 55, 149-152 (1995)
12. Desai, P.R., Ujjainwala, L.H., Carlstedt, S.C., Springer, G.F.: Anti-Thomsen-Friedenreich (T) antibody-based ELISA and its application to human breast carcinoma detection. J. Immunol. Methods 188, 75-85 (1995)
13. Kumar, S.R., Sauter, E.R., Quinn, T.P., Deutscher, S.L.: Thomsen-Friedenreich and Tn antigens in nipple fluid: carbohydrate biomarkers for breast cancer detection. Clin. Cancer Res. 11, 6868-6871 (2005)
14. Coon, J.S., Weinstein, R.S., Summers, J.L.: Blood group precursor T-antigen expression in human urinary bladder carcinoma. Am. J. Clin. Pathol. 77, 692-699 (1982)
15. Limas, C., Lange P.: T-antigen in normal and neoplastic urothelium. Cancer 58, 1236-1245 (1986)
16. Janssen, T., Petein, M., Van Velthoven, R., Van Leer, P., Fourmarier, M., Vanegas, J.P., Danguy, A., Schulman, C., Pasteels, J.L., Kiss, R.: Differential histochemical peanut agglutinin stain in benign and malignant human prostate tumors: relationship with prostatic specific antigen immunostain and nuclear DNA content. Human Pathol. 27, 1341-1347 (1996)
17. Zhang, S., Zhang, H.S., Cordon-Cardo, C., Reuter, V.E., Singhal, A.K., Lloyd, K.O., Livingston, P.O.: Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens. Int. J. Cancer 73, 50-56 (1997)
18. Cao, Y., Stosiek, P., Springer, G.F., Karsten, U.: Thomsen-Friedenreich- related carbohydrate antigens in normal adult human tissue: a systematic and comparative study. Histochem. Cell Biol. 106, 97-207 (1996)
19. Ghazizadeh, M., Oguro, T., Sasaki, Y., Aihara, K., Araki, T., Springer, G.F.: Immunohistochemical and ultrastructural localization of T antigen in ovarian tumors. Am. J. Clin. Pathol. 93, 315-321 (1990)
20. Sotozono, M.A., Okada, Y., Tsuji, T.: The Thomsen-Friedenreich antigen-related carbohydrate antigens in human gastric intestinal metaplasia and cancer. J. Histochem. Cytochem. 42, 1575-1584 (1994)
21. Baldus, S.E., Zirbes, T.K., Glossmann, J., Fromm, S., Hanisch, F.G., Monig, S.P., Schroder, W., Schneider, P.M., Flucke, U., Karsten, U., Thiele, J., Holscher, A.H., Dienes, H.P.: Immunoreactivity of monoclonal antibody BW835 represents a marker of progression and prognosis in early gastric cancer. Oncology 61, 147-155 (2001)
22. Moriyama, H., Nakano, H., Igawa, M., Nihira, H.: T antigen expression in benign hyperplasia and adenocarcinoma of the prostate. Urol. Int. 42, 120-123 (1987)
23. Wolf, M.F., Ludwig, A., Fritz, P., Schumacher, K.: Increased expression of Thomsen-Friedenreich antigens during tumor progression in breast cancer patients. Tumour Biol. 9, 190-194 (1988)
24. Langkilde, N.C., Wolf, H., Clausen, H., Kjeldsen, T., Orntoft, T.F.: Nuclear volume and expression of T-antigen, sialosyl-Tn-antigen, and Tn-antigen in carcinoma of the human bladder. Relation to tumor recurrence and progression. Cancer 69, 219-227 (1992)
25. Cao, Y., Karsten, U.R., Liebrich, W., Haensch, W., Springer, G.F., Schlag, P.M.: Expression of Thomsen-Friedenreich-related antigens in primary and metastatic colorectal carcinomas. A reevaluation. Cancer 76, 1700-1708 (1995)
26. Samuel, J., Longenecker, B.M.: Development of active specific immunotherapeutic agents based on cancer-associated mucins. Pharm. Biotechnol. 6, 875-890 (1995)
27. Springer, G.F., Tegtmeyer, H.: Origin of anti-Thomsen-Friedenreich (T) and Tn agglutinins in man and in White Leghorn chicks. Br. J. Haematol. 47, 453-460 (1981)
28. Kurtenkov, O., Miljukhina, L., Smorodin, J., Klaamas, K., Bovin, N., Ellamaa, M., Chuzmarov, V.: Natural IgM and IgG antibodies to Thomsen-Friedenreich (T) antigen in serum of patients with gastric cancer and blood donors-relation to Lewis (a,b) histo-blood group phenotype. Acta Oncol. 38, 939-943 (1999)
29. Adluri, S., Helling, F., Ogata, S., Zhang, S., Itzkowitz, S.H., Lloyd, K.O., Livingston, P.O.: Immunogenicity of synthetic TF-KLH (keyhole limpet hemocyanin) and sTn-KLH conjugates in colorectal carcinoma patients. Cancer Immunol. Immunother. 41, 185-192 (1995)
30. MacLean, G.D., Bowen-Yacyshyn, M.B., Samuel, J., Meikle, A., Stuart, G., Nation, J., Poppema, S., Jerry, M., Koganty, R., Wong, T., et al.: Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen-Friedenreich) determinant using a synthetic carbohydrate antigen. J. Immunother. 11, 292-305 (1992)
31. Yacyshyn, M.B., Poppema, S., Berg, A., MacLean, G.D., Reddish, M.A., Meikle, A., Longenecker, B.M.: CD69+ and HLA-DR+ activation antigens on peripheral blood lymphocyte populations in metastatic breast and ovarian cancer patients: correlations with survival following active specific immunotherapy. Int J Cancer 61, 470-474 (1995)
32. Slovin, S.F., Ragupathi, G., Musselli, C., Fernandez, C., Diani, M., Verbel, D., Danishefsky, S., Livingston, P., Scher, H.I.: Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer. Cancer Immunol. Immunother. 54, 694-702 (2005)
33. Ragupathi, G.: Carbohydrate antigens as targets for active specific immunotherapy. Cancer Immunol. Immunother. 43, 152-7 (1996)
34. Xu, Y., Gendler, S.J., Franco, A.: Designer glycopeptides for cytotoxic T cell-based elimination of carcinomas. J. Exp. Med. 99, 707-16 (2004)
35. Kurtenkov, O., Klaamas, K., Rittenhouse-Olson, K., Vahter, L., Sergejev, B., Miljukhina, L., Shljapnikova, L.: IgG immune response to tumor-associated carbohydrate antigens (TF, Tn, alphaGal) in patients with breast cancer: impact of neoadjuvant chemotherapy and relation to the survival. Exp. Oncol. 27, 136-140 (2005)
36. Ju, T., Brewer, K., D'Souza, A., Cummings, R.D., Canfield, W.M.: Cloning and expression of human core 1 beta1,3-galactosyltransferase. J. Biol. Chem. 277, 178-186 (2002)
37. Ju, T., Cummings, R.D., Canfield, W.M.: Purification, characterization, and subunit structure of rat core 1 Beta1,3-galactosyltransferase. J. Biol. Chem. 277, 169-77 (2002)
38. Lowe, J.B., Marth, J.D.: A genetic approach to Mammalian glycan function. Annu. Rev. Biochem. 72, 643-91 (2003)
39. Dahiya, R., Itzkowitz, S.H., Byrd, J.C., Kim, Y.S.: Mucin oligosaccharide biosynthesis in human colonic cancerous tissues and cell lines. Cancer 70, 1467-1476 (1992)
40. Brockhausen, I., Yang, J.M., Burchell, J., Whitehouse, C., Taylor-Papadimitriou, J.: Mechanisms underlying aberrant glycosylation of MUC1 mucin in breast cancer cells. Eur J Biochem 233, 607-17 (1995)
41. Whitehouse, C., Burchell, J., Gschmeissner, S., Brockhausen, I., Lloyd, K.O.: Taylor-Papadimitriou J. A transfected sialyltransferase that is elevated in breast cancer and localizes to the medial/trans-Golgi apparatus inhibits the development of core-2 based O-glycans. J Cell Biol 137, 1229-1241 (1997)
42. Martinez-Menarguez, J.A., Ballesta, J., Aviles, M., Madrid, J.F., Castells, M.T.: Influence of sulphate groups in the binding of peanut agglutinin. Histochemical demonstration with light- and electron-microscopy. Histochem J 24, 207-216 (1992)
43. Kuhns, W., Jain, R.K., Matta, K.L., Paulsen, H., Baker, M.A., Geyer, R., Brochhausen, I.: Characterization of a novel mucin suphotransferase activity synthesizing suphated O-glycan core 1, 3-suphate-galβ1-GalNAcα-R. Glycobiology 5, 689-697 (1995)
44. Kumamoto, K., Goto, Y., Sekikawa, K., Takenoshita, S., Ishida, N., Kawakita, M., Kannagi, R.: Increased expression of UDP-galactose transporter messenger RNA in human colon cancer tissues and its implication in synthesis of Thomsen-Friedenreich antigen and sialyl Lewis A/X determinants. Cancer Res. 61, 4620-4627 (2001)
45. Rivinoja, A., Kokkonen, N., Kellokumpu, I., Kellokumpu, S.: Elevated Golgi pH in breast and colorectal cancer cells correlates with the expression of oncofetal carbohydrate T-antigen. J. Cell Physiol. 208, 167-74 (2006)
46. Axelsson, M.A., Karlsson N.G., Steel D.M., Ouwendijk J., Nilsson T., Hansson G.C.: Neutralization of pH in the Golgi apparatus causes redistribution of glycosyltransferases and changes in the O-glycosylation of mucins. Glycobiology 11, 633-644 (2001)
47. Ju, T., Cummings, R.D.: A unique molecular chaperone Cosmc required for activity of the mammalian core 1 beta 3-galactosyltransferase. Proc. Natl. Acad. Sci. U.S.A. 99, 16613-16618 (2002)
48. Ju, T., Cummings, R.D.: Protein glycosylation: chaperone mutation in Tn syndrome. Nature 437, 1252 (2005)
49. Schietinger, A., Philip M., Yoshida B.A., Azadi P., Liu H., Meredith S.C., Schreiber H.: A mutant chaperone converts a wild-type protein into a tumor-specific antigen. Science 314, 304-308 (2006)
50. Ryder, S.D., Smith, J.A., Rhodes J.M.: Peanut lectin is a mitogen for normal human colonic epithelium and HT29 colorectal cancer cells. J. Natl. Cancer Inst. 84, 1410-1416 (1992)
51. Ryder, S.D., Parker, N., Eccleston, D., Haqqani, M.T., Rhodes J.M.: Peanut lectin (PNA) stimulates proliferation in colonic explants from patients with ulcerative colitis, Crohn's disease and colonic polyps. Gastroenterology 106, 117-124 (1994)
52. Yu, L.G., Milton, J.D., Fernig, D.G., Rhodes, J.M.: Opposite effects on human colon cancer cell proliferation of two dietary Thomsen-Friedenreich antigen-binding lectins. J. Cell. Physiol. 186, 282-287 (2001)
53. Yu, L.G., Fernig, D.G., White, M.R.H., Spiller, D.G., Evans, R.C., Appleton, P., Grierson I., Smith J.A., Davies H., Gerasimenko O.V., Peterson O.H., Milton, J.D., Rhodes, J.M.: Edible mushroom (Agaricus bisporus) lectin, which reversibly inhibits epithelial cell proliferation, blocks NLS-dependent nuclear protein import. J. Biol. Chem. 274, 4890-4899 (1999)
54. Yu, L., Fernig, D.G., Smith, J.A., Milton, J.D., Rhodes, J.M.: Reversible inhibition of proliferation of epithelial cell lines by Agaricus bisporus (edible mushroom) lectin. Cancer Res. 53, 4627-4632 (1993)
55. Pusztai, A.: Plant Lectins, pp. 78-95. Cambridge University Press, Cambridge, UK (1991)
56. Evans, R.C., Fear, S., Ashby, D., Hackett. A., Williams, E., Van der Vliet M., Dunstan F.D.J., Rhodes J.M.: Diet and colorectal cancer: an investigation of the lectin/galactose hypothesis. Gastroenterology 122, 1784-1792 (2002)
57. Liu, F.T., Rabinovich, G.A.: Galectins as modulators of tumour progression. Nat. Rev. Cancer. 5, 29-41 (2005)
58. Danguy, A., Camby, I., Kiss, R.: Galectins and cancer. Biochim. Biophys. Acta 1572, 285-293 (2002)
59. Van den Brule, F., Califice, S., Castronovo, V.: Expression of galectins in cancer: a critical review. Glycoconj. J. 19, 537-542 (2004)
60. Califice, S., Castronovo, V., Van Den Brule, F.: Galectin-3 and cancer. Int. J. Oncol. 25, 983-992 (2004)
61. Takenaka, Y., Fukumori, T., Raz, A.: Galectin-3 and metastasis. Glycoconj. J. 19, 543-549 (2004)
62. Iurisci, I., Tinari, N., Natoli, C., Angelucci, D., Cianchetti, E., Iacobelli, S.: Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clin. Cancer Res. 6, 1389-1393 (2000)
63. Vereecken, P., Zouaoui Boudjeltia, K., Debray, C., Awada, A., Legssyer, I., Sales, F., Petein, M., Vanhaeverbeek, M., Ghanem, G., Heenen, M.: High serum galectin-3 in advanced melanoma: preliminary results. Clin. Exp. Dermatol. 31, 105-109 (2006)
64. Leffler, H., Barondes, S.H.: Specificity of binding of three soluble rat lung lectins to substituted and unsubstituted mammalian beta-galactosides. J Biol Chem 261, 10119-10126 (1986)
65. Sparrow, C.P., Leffler, H., Barondes, S.H.: Multiple soluble beta-galactoside-binding lectins from human lung. J. Biol. Chem. 262, 7383-7390 (1987)
66. Glinsky, V.V., Glinsky, G.V., Huflejt, M.E., Glinskii, O.V., Deutscher, S.L., Quinn, T.P.: The role of Thomsen-Friedenreich antigen in adhesion of human breast and prostate cancer cells to the endothelium. Cancer Res. 61, 4851-4857 (2001)
67. Glinsky, V.V., Huflejt, M.E., Glinsky, G.V., Deutscher, S.L., Quinn, T.P.: Effects of Thomsen-Friedenreich antigen-specific peptide P-30 on beta-galactoside-mediated homotypic aggregation and adhesion to the endothelium of MDA-MB-435 human breast carcinoma cells. Cancer Res. 60, 2584-2588 (2000)
68. Sangeetha, S.R., Appukuttan, P.S.: IgA1 is the premier serum glycoprotein recognized by human galectin-1 since T antigen (Galbeta1->3GalNAc-) is far superior to non-repeating N-acetyl lactosamine as ligand. Int. J. Biol. Macromol. 35, 269-276 (2005)
69. Jeschke, U., Karsten, U., Wiest, I., Schulze, S., Kuhn, C., Friese, K., Walzel, H.: Binding of galectin-1 (gal-1) to the Thomsen-Friedenreich (TF) antigen on trophoblast cells and inhibition of proliferation of trophoblast tumor cells in vitro by gal-1 or an anti-TF antibody. Histochem. Cell Biol. 126, 437-444 (2006)
70. Yu, L.G., Andrews, N., Zhao, Q., McKean, D., Williams, J.F., Connor, L.J., Gerosimenko, O.V., Hilkens, J., Hirabayashi, J., Kasai, K., Rhodes, J.M.: Galectin-3 interaction with Thomsen-Friedenreich oligosaccharide on cancer-associated MUC1 causes increased cancer cell-endothelial adhesion. J. Biol. Chem. 282, 773-781 (2007)
71. Perillo, N.L., Marcus, M.E., Baum, L.G.: Galectins: versatile modulators of cell adhesion, cell proliferation, and cell death. J. Mol. Med. 76, 402-412 (1998)
72. Inohara, H., Akahani, S., Raz, A.: Galectin-3 stimulates cell proliferation. Exp. Cell Res. 245, 294-302 (1998)
73. Maeda, N., Kawada, N., Seki, S., Arakawa, T., Ikeda, K., Iwao, H., Okuyama, H., Hirabayashi, J., Kasai, K., Yoshizato, K.: Stimulation of proliferation of rat hepatic stellate cells by galectin-1 and galectin-3 through different intracellular signaling pathways. J. Biol. Chem. 278, 18938-18944 (2003)
74. Honjo, Y., Nangia-Makker, P., Inohara, H., Raz, A.: Down-regulation of galectin-3 suppresses tumorigenicity of human breast carcinoma cells. Clin. Cancer Res. 7, 661-668 (2001)
75. Biron, V.A., Iglesias, M.M., Troncoso, M.F., Besio-Moreno, M., Patrignani, Z.J., Pignataro, O.P., Wolfenstein-Todel, C.: Galectin-1 biphasic growth regulation of Leydig tumor cells. Glycobiology 16, 810-821 (2006)
76. Kopitz, J., von Reitzenstein, C., Andre, S., Kaltner, H., Uhl, J., Ehemann, V., Cantz, M., Gabius, H.J.: Negative regulation of neuroblastoma cell growth by carbohydrate-dependent surface binding of galectin-1 and functional divergence from galectin-3. J. Biol. Chem. 276, 35917-35923 (2001)
77. Hammer, D.A.: Leukocyte adhesion: what's the catch? Curr. Biol. 15, R96-R99 (2005)
78. Kannagi, R.: Regulatory roles of carbohydrate ligands for selectins in the homing of lymphocytes. Curr. Opin. Struck. Biol. 12, 599-608 (2002)
79. Krause, T., Turner, G.A.: Are selectins involved in metastasis? Clin. Exp. Metastasis 17, 183-192 (1999)
80. Nair, K.S., Naidoo, R., Chetty, R.: Expression of cell adhesion molecules in oesophageal carcinoma and its prognostic value. J. Clin. Pathol. 58, 343-351 (2005)
81. Kannagi, R., Izawa, M., Koike, T., Miyazaki, K., Kimura, N.: Carbohydrate-mediated cell adhesion in cancer metastasis and angiogenesis. Cancer Sci. 95, 377-384 (2004)
82. Giavazzi, R., Foppolo, M., Dossi, R., Remuzzi, A.: Rolling and adhesion of human tumor cells on vascular endothelium under physiological flow conditions. J. Clin. Invest. 92, 3038-3044 (1993)
83. Khaldoyanidi, S.K., Glinsky, V.V., Sikora, L., Glinskii, A.B., Mossine, V.V., Quinn, T.P., Glinsky, G.V., Sriramarao, P.: MDA-MB-435 human breast carcinoma cell homo- and heterotypic adhesion under flow conditions is mediated in part by Thomsen-Friedenreich antigen-galectin-3 interactions. J. Biol. Chem. 278, 4127-4134 (2003)
84. Thorlacius, H., Prieto, J., Raud, J., Gautam, N., Patarroyo, M., Hedqvist, P., Lindbom, L.: Tumor cell arrest in the microcirculation: lack of evidence for a leukocyte-like rolling adhesive interaction with vascular endothelium in vivo. Clin. Immunol. Immunopathol. 83, 68-76 (1997)
85. Glinsky, V.V., Glinsky, G.V., Glinskii, O.V., Huxley, V.H., Turk, J.R., Mossine, V.V., Deutscher, S.L., Pienta, K.J., Quinn, T.P.: Intravascular metastatic cancer cell homotypic aggregation at the sites of primary attachment to the endothelium. Cancer Res. 63, 3805-3811 (2003)
86. Zou, J., Glinsky, V.V., Landon, L.A., Matthews, L., Deutscher, S.L.: Peptides specific to the galectin-3 carbohydrate recognition domain inhibit metastasis-associated cancer cell adhesion. Carcinogenesis 26, 309-318 (2005)
87. Heimburg, J., Yan, J., Morey, S., Glinskii, O.V., Huxley, V.H., Wild, L., Klick, R., Roy, R., Glinsky, V.V., Rittenhouse-Olson K.: Inhibition of spontaneous breast cancer metastasis by anti-Thomsen-Friedenreich antigen monoclonal antibody JAA-F11. Neoplasia 8, 939-948 (2006)
88. Glinskii, O.V., Huxley, V.H., Glinsky, G.V., Pienta, K.J., Raz, A., Glinsky, V.V.: Mechanical entrapment is insufficient and intercellular adhesion is essential for metastatic cell arrest in distant organs. Neoplasia 7, 522-527 (2005)
89. Shigeoka, H., Karsten, U., Okuno, K., Yasutomi, M.: Inhibition of liver metastases from neuraminidase-treated colon 26 cells by an anti-Thomsen- Friedenreich-specific monoclonal antibody. Tumour Biol. 20, 139-146 (1999)
90. Shekhar, M.P., Nangia-Makker, P., Tait, L., Miller, F., Raz, A.: Alterations in galectin-3 expression and distribution correlate with breast cancer progression: functional analysis of galectin-3 in breast epithelial-endothelial interactions. Am. J. Pathol. 165, 1931-1941 (2004)
91. Singh, R., Campbell, B.J., Yu, L.G., Fernig, D.G., Milton, J.D., Goodlad, R.A., FitzGerald, A.J., Rhodes, JM.: Cell surface-expressed Thomsen-Friedenreich antigen in colon cancer is predominantly carried on high molecular weight splice variants of CD44. Glycobiology 11, 587-592 (2001)
92. Baldus, S.E., Hanisch, F.G., Kotlarek, G.M., Zirbes, T.K., Thiele, J., Isenber, J., Karsten, U.R., Devine, P.L., Dienes, HP.: Coexpression of MUC1 mucin peptide core and the Thomsen-Friedenreich antigen in colorectal neoplasms. Cancer 82, 1019-1027 (1998)
93. Jothy, S.: CD44 and its partners in metastasis. Clin. Exp. Metastasis 20, 195-201 (2003)
94. Heider, K.H., Kuthan, H., Stehle, G., Munzert, G.: CD44v6: a target for antibody-based cancer therapy. Cancer. Immunol. Immunother. 53, 567-579 (2004)
95. Bresalier, R.S., Niv, Y., Byrd, J.C., Duh, Q.Y., Toribara, N.W., Rockwell, R.W., Dahiya, R., Kim, Y.S.: Mucin production by human colonic carcinoma cells correlates with their metastatic potential in animal models of colon cancer metastasis. J. Clin. Invest. 87, 1037-1045 (1991)
96. Nakamori, S., Ota, DM., Cleary, K.R., Shirotani, K., Irimura, T.: MUC1 mucin expression as a marker of progression and metastasis of human colorectal carcinoma. Gastroenterology 106, 353-361 (1994)
97. Karsten, U., Von Mensdorff-Pouilly, S., Goletz, S.: What makes MUC1 a tumor antigen? Tumour Biol. 26, 217-20 (2005)
98. Ponta, H., Sherman, L., Herrlich, P.A.: CD44: from adhesion molecules to signalling regulators. Nat. Rev., Mol. Cell Biol. 4, 33-45 (2003)
99. Zöller, M.: CD44 physiological expression of distinctisoforms as evidence for organ-specific metastatsis formation. J. Mol. Med. 73, 425 (1995)
100. Gunthert, U., Hofmann, M., Rudy, W., Reber, S., Zöller M., Haussmann, I., Matzku, S., Wenzel, A., Ponta, H., Herrlich, P. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65, 13-24 (1991)
101. Reeder, J.A., Gotley, D.C., Walsh, M.D., Fawcett, J., Antalis, T.M.: Expression of antisense CD44 variant 6 inhibits colorectal tumor metastasis and tumor growth in a wound environment. Cancer Res. 58, 3719-3726 (1998)
102. Taylor-Papadimitriou, J., Burchell, J., Miles, D.W., Dalziel, M.: MUC1 and cancer. Biochim. Biophys. Acta 1455, 301-313 (1999)
103. Hilkens, J., Ligtenberg, M.J., Vos, H.L., Litvinov, S.V.: Cell membrane-associated mucins and their adhesion-modulating property. Trends. Biochem. Sci. 17, 359-363 (1992)
104. Lloyd, K.O., Burchell, J., Kudryashov, V., Yin, B.W., Taylor-Papadimitriou, J.: Comparison of O-linked carbohydrate chains in MUC-1 mucin from normal breast epithelial cell lines and breast carcinoma cell lines. Demonstration of simpler and fewer glycan chains in tumor cells. J. Biol. Chem. 271, 33325-33334 (1996)
105. Karsten, U., Butschak, G., Cao, Y., Goletz, S., Hanisch, F.G.: A new monoclonal antibody (A78-G/A7) to the Thomsen-Friedenreich pan-tumor antigen. Hybridoma 14, 37-44 (1995)
106. Hanisch, F.G., Stadie, T., Bosslet, K.: Monoclonal antibody BW835 defines a site-specific Thomsen-Friedenreich disaccharide linked to threonine within the VTSA motif of MUC1 tandem repeats. Cancer Res. 55, 4036-4040 (1995)
107. Baldus, S.E., Hanisch, F.G., Monaca, E., Karsten, U.R., Zirbes, T.K., Thiele J., Dienes H.P.: Immunoreactivity of Thomsen-Friedenreich (TF) antigen in human neoplasms: the importance of carrier-specific glycotope expression on MUC1. Histol. Histopathol. 14, 1153-1158 (1999)
108. Bhavanandan, V.P., Umemoto, J., Davidson, E.A.: Characterization of an endo-alpha-N-acetyl galactosaminidase from Diplococcus pneumoniae. Biochem. Biophys. Res. Commun. 70, 738-745 (1976)
109. Baldus, S.E., Wienand, J.R., Werner, J.P., Landsberg, S., Drebber, U., Hanisch, F.G., Dienes, H.P.: Expression of MUC1, MUC2 and oligosaccharide epitopes in breast cancer: prognostic significance of a sialylated MUC1 epitope. Int. J. Oncol. 27, 1289-1297 (2005)
110. Becker, J.W., Erickson, H.P., Hoffman, S., Cunningham, B.A., Edelman, G.M.: Topology of cell adhesion molecules. Proc. Natl. Acad. Sci. U. S. A. 86, 1088-1092 (1989)
111. Ligtenberg, M.J., Buijs, F., Vos, H.L., Hilkens, J.: Suppression of cellular aggregation by high levels of episialin. Cancer Res. 52, 2318-2324 (1992)
112. Wesseling, J., Van der Valk, S.W., Hilkens, J.: A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. Mol. Biol. Cell 7, 565-577 (1996)
113. Kondo, K., Kohno, N., Yokoyama, A., Hiwada, K.: Decreased MUC1 expression induces E-cadherin-mediated cell adhesion of breast cancer cell lines. Cancer Res. 58, 2014-2019 (1998)
114. Li, Y.S., Kaneko, M., Sakamoto, D.G., Takeshima, Y., Inai, K.: The reversed apical pattern of MUC1 expression is characteristics of invasive micropapillary carcinoma of the breast. Breast Cancer 13, 58-63 (2006)
115. Xia, L., Ju, T., Westmuckett, A., An, G., Ivanciu, L., McDaniel, J.M., Lupu, F., Cummings, R.D., McEver, R.P.: Defective angiogenesis and fatal embryonic hemorrhage in mice lacking core 1-derived O-glycans. J. Cell Biol. 164, 451-459 (2004)
116. Nangia-Makker, P., Hogan, V., Honjo, Y., Baccarini, S., Tait, L., Bresalier, R., Raz, A.: Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. J. Natl. Cancer Inst. 94, 1854-1862 (2002)
117. Nangia-Makker, P, Honjo, Y, Sarvis, R, Akahani, S, Hogan, V, Pienta, KJ, Raz, A.: Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am. J. Pathol. 156, 899-909 (2000)
118. Thijssen, V.L., Postel, R., Brandwijk, R.J., Dings, R.P., Nesmelova, I., Satijn, S., Verhofstad, N., Nakabeppu, Y., Baum, L.G., Bakkers, J., Mayo, K.H., Poirier, F., Griffioen, A.W.: Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc. Natl. Acad. Sci. U.S.A. 103, 15975-15980 (2006)